SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

PLUS THERAPEUTICS, INC.
Date: Aug. 5, 2025 · CIK: 0001095981 · Accession: 0000000000-25-008211

Offering / Registration Process Regulatory Compliance Financial Reporting

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

Date
August 5, 2025
Author
Division of
Form
UPLOAD
Company
PLUS THERAPEUTICS, INC.

Letter

Re: Plus Therapeutics, Inc. Draft Registration Statement on Form S-1 Submitted August 4, 2025 CIK No. 0001095981 Dear Andrew Sims:

August 5, 2025

Andrew Sims Chief Financial Officer Plus Therapeutics, Inc. 2710 Reed Road, Suite 160 Houston, TX 77002

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Aaron Schleicher, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 August 5, 2025

Andrew Sims
Chief Financial Officer
Plus Therapeutics, Inc.
2710 Reed Road, Suite 160
Houston, TX 77002

 Re: Plus Therapeutics, Inc.
 Draft Registration Statement on Form S-1
 Submitted August 4, 2025
 CIK No. 0001095981
Dear Andrew Sims:

 This is to advise you that we do not intend to review your registration
statement.

 We request that you publicly file your registration statement at least
two business
days prior to the requested effective date and time. Please refer to Rules 460
and 461
regarding requests for acceleration. We remind you that the company and its
management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review,
comments, action or absence of action by the staff.

 Please contact Daniel Crawford at 202-551-7767 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Aaron Schleicher, Esq.
</TEXT>
</DOCUMENT>